NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xingeyuan Biotechnology

Xingeyuan Biotechnology

Private
NanjingHealthcare & Life Scienceshttps://singleron.bio/

Last Round

Series B

Nov 8, 2021

Total Funding Raised

$170M

Company Overview

Singleron Biotechnologies is a biotechnology company that specializes in single-cell multi-omics analysis technologies, providing molecular diagnostic products and automated equipment for clinical diagnosis, health management, and drug development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

single-cell sequencingmulti-omicssingle-cell analysisbioinformatics softwaremicrofluidicsscRNA-seqcellular profilingdrug discovery toolsbiomarker discoverylab automationgenomics platformclinical diagnosticsrazor-and-blade modellife science reagentssingle-cell database

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xingeyuan Biotechnology Comps

Public and private peers based on sector, stage, and business model.

Xingeyuan Biotechnology comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Xingeyuan Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 8, 2021
Series A ExtensionDec 29, 2020
Series A ExtensionNov 9, 2020
Series ASep 6, 2020
VC RoundJun 20, 2019
Seed
May 1, 2018

Xingeyuan Biotechnology Investors

Notable investors and investment history

Xingeyuan Biotechnology investors
InvestorRounds
CDH InvestmentsSeries A Extension, Series A, Series B
Lake Bleu CapitalSeries B
Firstred CapitalSeries B
MSA CapitalSeries B
ARCH Venture PartnersSeries A, Series B
Frees FundVC Round, Seed
ARCH Venture PartnersSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 9, 2020

    $10M raised from CDG Capital, CDH Investments, Lilly Asia Ventures, and SB China Capital.

  • Sep 10, 2020

    $30M round led by Lilly Asia Ventures

Xingeyuan Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xingeyuan Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xingeyuan Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Year Founded2018
Last FundingNov 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.